Vir Biotechnology, Inc. Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
Vir Biotechnology, Inc. (VIR) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of -$1.12 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2026-08-05
- Vir Biotechnology, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-06-30 was -$1.12M.
- Vir Biotechnology, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-03-31 was -$1.43M.
- Vir Biotechnology, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-09-30 was $310.00K, a 92.26% decline year-over-year.
- Vir Biotechnology, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-06-30 was -$246.00K.
- Vir Biotechnology, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2023 was $8.31M.
- Vir Biotechnology, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2022 was -$8.02M, a 4582.12% decline from fiscal 2021.
- Vir Biotechnology, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2021 was $179.00K.
- Vir Biotechnology, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2020 was -$677.00K.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.12M 10-Q · filed 2026-08-05 | -$2.54M 10-Q · filed 2026-08-05 | ||
| 2026-03-31 | -$1.43M 10-Q · filed 2026-05-07 | |||
| 2025-09-30 | $310.00K 10-Q · filed 2025-11-05 | $64.00K derived: sum of 2 quarters · filed 2026-08-05 | -$194.00K 10-Q · filed 2025-11-05 | |
| 2025-06-30 | -$246.00K 10-Q · filed 2026-08-05 | -$504.00K 10-Q · filed 2026-08-05 | ||
| 2025-03-31 | -$258.00K 10-Q · filed 2026-05-07 | |||
| 2024-09-30 | $4.01M 10-Q · filed 2025-11-05 | $3.52M derived: sum of 2 quarters · filed 2025-11-05 | $1.94M 10-Q · filed 2025-11-05 | $3.03M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | -$482.00K 10-Q · filed 2025-08-06 | -$2.06M 10-Q · filed 2025-08-06 | -$979.00K derived: sum of 3 quarters · filed 2025-08-06 | $24.00K derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | -$1.58M 10-Q · filed 2024-05-03 | -$497.00K derived: sum of 2 quarters · filed 2024-05-03 | $506.00K derived: sum of 3 quarters · filed 2024-05-03 | $822.00K derived: sum of 4 quarters · filed 2024-05-03 |
| 2023-12-31 | $1.08M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $2.09M derived: sum of 2 quarters · filed 2024-02-26 | $2.40M derived: sum of 3 quarters · filed 2024-02-26 | $8.31M 10-K · filed 2024-02-26 |
| 2023-09-30 | $1.00M 10-Q · filed 2023-11-03 | $1.32M derived: sum of 2 quarters · filed 2023-11-03 | $7.22M 10-Q · filed 2023-11-03 | $9.98M derived: sum of 4 quarters · filed 2024-05-03 |
| 2023-06-30 | $316.00K 10-Q · filed 2023-08-04 | $6.22M 10-Q · filed 2023-08-04 | $8.98M derived: sum of 3 quarters · filed 2024-05-03 | $4.65M derived: sum of 4 quarters · filed 2024-05-03 |
| 2023-03-31 | $5.90M 10-Q · filed 2024-05-03 | $8.66M derived: sum of 2 quarters · filed 2024-05-03 | $4.33M derived: sum of 3 quarters · filed 2024-05-03 | $1.59M derived: sum of 4 quarters · filed 2024-05-03 |
| 2022-12-31 | $2.76M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | -$1.57M derived: sum of 2 quarters · filed 2024-02-26 | -$4.32M derived: sum of 3 quarters · filed 2024-02-26 | -$8.02M 10-K · filed 2024-02-26 |
| 2022-09-30 | -$4.33M 10-Q · filed 2023-11-03 | -$7.08M derived: sum of 2 quarters · filed 2023-11-03 | -$10.78M 10-Q · filed 2023-11-03 | -$10.57M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-06-30 | -$2.75M 10-Q · filed 2023-08-04 | -$6.45M 10-Q · filed 2023-08-04 | -$6.25M derived: sum of 3 quarters · filed 2024-02-26 | -$6.22M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-03-31 | -$3.71M 10-Q · filed 2023-05-08 | -$3.50M derived: sum of 2 quarters · filed 2024-02-26 | -$3.47M derived: sum of 3 quarters · filed 2024-02-26 | -$3.50M derived: sum of 4 quarters · filed 2024-02-26 |
| 2021-12-31 | $208.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $235.00K derived: sum of 2 quarters · filed 2024-02-26 | $205.00K derived: sum of 3 quarters · filed 2024-02-26 | $179.00K 10-K · filed 2024-02-26 |
| 2021-09-30 | $27.00K 10-Q · filed 2022-11-03 | -$3.00K derived: sum of 2 quarters · filed 2022-11-03 | -$29.00K 10-Q · filed 2022-11-03 | -$822.00K derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | -$30.00K 10-Q · filed 2022-08-09 | -$56.00K 10-Q · filed 2022-08-09 | -$849.00K derived: sum of 3 quarters · filed 2023-02-28 | -$1.04M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | -$26.00K 10-Q · filed 2022-05-05 | -$819.00K derived: sum of 2 quarters · filed 2023-02-28 | -$1.01M derived: sum of 3 quarters · filed 2023-02-28 | -$1.55M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | -$793.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$983.00K derived: sum of 2 quarters · filed 2023-02-28 | -$1.53M derived: sum of 3 quarters · filed 2023-02-28 | -$677.00K 10-K · filed 2023-02-28 |
| 2020-09-30 | -$190.00K 10-Q · filed 2021-11-04 | -$733.00K derived: sum of 2 quarters · filed 2021-11-04 | $116.00K 10-Q · filed 2021-11-04 | -$566.00K derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | -$543.00K 10-Q · filed 2021-08-05 | $306.00K 10-Q · filed 2021-08-05 | -$376.00K derived: sum of 3 quarters · filed 2022-02-28 | -$535.00K derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $849.00K 10-Q · filed 2021-05-06 | $167.00K derived: sum of 2 quarters · filed 2022-02-28 | $8.00K derived: sum of 3 quarters · filed 2022-02-28 | $153.00K derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | -$682.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$841.00K derived: sum of 2 quarters · filed 2022-02-28 | -$696.00K derived: sum of 3 quarters · filed 2022-02-28 | -$587.00K 10-K · filed 2022-02-28 |
| 2019-09-30 | -$159.00K 10-Q · filed 2020-11-10 | -$14.00K derived: sum of 2 quarters · filed 2020-11-10 | $95.00K 10-Q · filed 2020-11-10 | $122.00K derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $145.00K 10-Q · filed 2020-08-11 | $254.00K 10-Q · filed 2020-08-11 | $281.00K derived: sum of 3 quarters · filed 2021-02-25 | $256.00K derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $109.00K 10-Q · filed 2020-05-12 | $136.00K derived: sum of 2 quarters · filed 2021-02-25 | $111.00K derived: sum of 3 quarters · filed 2021-02-25 | |
| 2018-12-31 | $27.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $2.00K derived: sum of 2 quarters · filed 2021-02-25 | -$14.00K 10-K · filed 2021-02-25 | |
| 2018-09-30 | -$25.00K 10-Q · filed 2019-11-19 | -$41.00K 10-Q · filed 2019-11-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |